DK1526856T3 - Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi - Google Patents

Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi

Info

Publication number
DK1526856T3
DK1526856T3 DK03764245T DK03764245T DK1526856T3 DK 1526856 T3 DK1526856 T3 DK 1526856T3 DK 03764245 T DK03764245 T DK 03764245T DK 03764245 T DK03764245 T DK 03764245T DK 1526856 T3 DK1526856 T3 DK 1526856T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
cancer therapy
estetrol
derivatives
estetrol derivatives
Prior art date
Application number
DK03764245T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of DK1526856T3 publication Critical patent/DK1526856T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03764245T 2002-07-12 2003-07-11 Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi DK1526856T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077812 2002-07-12
EP03075435 2003-02-14
PCT/NL2003/000513 WO2004006936A1 (en) 2002-07-12 2003-07-11 Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy

Publications (1)

Publication Number Publication Date
DK1526856T3 true DK1526856T3 (da) 2008-03-10

Family

ID=30116907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03764245T DK1526856T3 (da) 2002-07-12 2003-07-11 Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi

Country Status (13)

Country Link
US (2) US9034854B2 (da)
EP (1) EP1526856B1 (da)
CN (1) CN100374116C (da)
AT (1) ATE382356T1 (da)
AU (1) AU2003253506A1 (da)
CA (1) CA2492287C (da)
CY (1) CY1107906T1 (da)
DE (1) DE60318447T2 (da)
DK (1) DK1526856T3 (da)
ES (1) ES2299730T3 (da)
PT (1) PT1526856E (da)
SI (1) SI1526856T1 (da)
WO (1) WO2004006936A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034854B2 (en) * 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
DE102007032468A1 (de) * 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
RU2422915C1 (ru) * 2010-02-12 2011-06-27 Юрий Николаевич Бордюшков Способ торможения пролиферативного процесса в ткани предстательной железы в эксперименте
WO2012164096A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
BR112013030833B1 (pt) 2011-06-01 2019-09-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
EP3046928B1 (en) 2013-09-18 2017-02-08 Crystal Pharma, S.A.U. Process for the preparation of estetrol
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (en) * 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
CN112351782A (zh) * 2018-05-02 2021-02-09 埃斯特拉私人有限责任公司 晚期雌激素受体阳性乳腺癌的治疗
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
ES2247710T3 (es) 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
JP2003527310A (ja) 1999-04-16 2003-09-16 イエナフアルム ゲーエムベーハー ウント ツェーオー． カーゲー エストロゲンを局部的に皮内投与するための医薬品組成物または化粧品組成物
WO2000073416A1 (en) 1999-05-28 2000-12-07 University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20020012710A1 (en) * 1999-11-29 2002-01-31 Rimonest Ltd. Pomegranate products useful in improving health and methods of use thereof
US7371385B2 (en) 2000-05-12 2008-05-13 Oregon Health & Science University Method of treating immune pathologies with low dose estrogen
CA2462081A1 (en) * 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
AU2002240949A1 (en) * 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US6593321B2 (en) * 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
US9034854B2 (en) * 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US8987240B2 (en) * 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
DK1624878T3 (da) * 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte

Also Published As

Publication number Publication date
CN100374116C (zh) 2008-03-12
WO2004006936A8 (en) 2005-03-03
DE60318447T2 (de) 2009-01-02
PT1526856E (pt) 2008-04-11
AU2003253506A1 (en) 2004-02-02
CA2492287A1 (en) 2004-01-22
US20060063723A1 (en) 2006-03-23
ES2299730T3 (es) 2008-06-01
SI1526856T1 (sl) 2008-04-30
US20150133413A1 (en) 2015-05-14
CA2492287C (en) 2011-12-13
EP1526856B1 (en) 2008-01-02
WO2004006936A1 (en) 2004-01-22
ATE382356T1 (de) 2008-01-15
EP1526856A1 (en) 2005-05-04
DE60318447D1 (de) 2008-02-14
US9034854B2 (en) 2015-05-19
CY1107906T1 (el) 2013-09-04
US10201611B2 (en) 2019-02-12
CN1681513A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
TW200616650A (en) Semi-solid delivery vehicle and pharmaceutical compositions
TW200612987A (en) Combination treatment for non-hematologic malignancies
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
UY28662A1 (es) Agente endoparasiticida para administracion topica
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
SE0400346D0 (sv) Steroids for cancer treatment
SG152257A1 (en) Topical preparation containing ambroxol
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
TN2009000119A1 (en) Combination drug
BRPI0409588A (pt) composto, composição farmacêutica, métodos para ligar seletivamente ao receptor beta de estrogênio em um paciente, para tratar um paciente acometido de uma condição de enfermidade mediada com um receptor beta de estrogênio, para tratar cáncer de próstata e hiperplasia prostática benigna em um paciente, e, uso de um composto
DE60311665D1 (de) Pharmazeutische zusammensetzungen
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer